$5 Million Common Stock Offering for Endonovo Therapeutics Designed to Advance SofPulse® Process for Medical Reimbursement
April 11, 2022 09:08 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, April 11, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced significant advancement in the of process to obtain medical reimbursements for its...
Endonovo Therapeutics Inc. (ENDV) Announces it has filed a Regulation A+ Financing & Retained Dalmore Group to Provide Operations & Compliance
February 16, 2022 09:10 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTC-ENDV) an Innovative Medical Devices developer and distributor is pleased to announce it has filed a Regulation A+...
Endonovo Therapeutics Issues Shareholder Update
October 12, 2021 16:05 ET
|
Endonovo Therapeutics, Inc.
High-Growth Acquisition Approaches Completion, Expected To Augment Core Business And Drive Long-Term Shareholder Value Los Angeles, CA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc....
Stanford University Orthopedic Study Collaboration with Endonovo Therapeutics SofPulse® Devices Moves Forward
May 11, 2021 08:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, May 11, 2021 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced completion of Shipment of SofPulse® tPEMF Devices for use in...
Endonovo Therapeutics Announces First Quarter Fiscal 2020 Financial Results
June 15, 2020 08:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, June 15, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announces financial and operating results for the first quarter...
Endonovo Therapeutics Announces Eight Additional Hospitals Approved Use of SofPulse® at Their Facilities
April 16, 2020 08:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, April 16, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced the addition of eight new hospitals Endonovo’s SofPulse®...
Endonovo Therapeutics seeks Intensive Care Unit Partners for Investigational Adjunctive Treatment for Severe Respiratory Inflammatory Complications for COVID-19 Patients.
March 25, 2020 08:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, March 25, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announces the intent to distribute of SofPulse®...
Endonovo Therapeutics announces its collaboration with Major Universities for the Evaluation of SofPulse® for Orthopedic Surgeries
February 10, 2020 07:30 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced their SofPulse® device is being evaluated at major...
Endonovo Therapeutics Expands SofPulse® Sales to Plastic Surgery Centers
January 30, 2020 07:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced sales of SofPulse® units to multiple Plastic Surgery...
Endonovo Therapeutics Announces First SofPulse® Sales to a Veterans Medical Center
January 27, 2020 07:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced initial sales of SofPulse® units into a VA hospital in...